V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220008116 | 220020458 | 1.55 | null | Palliative (P) | 2014-03-04 | 2014-03-04 | RAVVA TRIAL | 02 | N | 220033856 | RAVVA TRIAL |
| 220008117 | 220020458 | 1.7 | 54.2 | Palliative (P) | 2017-05-11 | 2017-05-31 | ECX | N | N | 220033856 | ECX |
| 220008118 | 220020458 | null | null | Curative (C) | 2016-02-05 | 2016-03-17 | Cytarabine High Dose | N | N | 220033856 | CYTARABINE HIGH DOSE |
| 220008119 | 220003251 | 1.65 | null | Palliative (P) | 2013-01-20 | 2013-01-23 | FLUOROURACIL + OXALIPLATIN | N | N | 220033862 | OXALIPLATIN + MDG |
| 220008120 | 220003252 | 1.65 | 84.6 | Palliative (P) | 2014-07-15 | 2014-07-20 | ECX | 02 | Y | 220033863 | ECX |
| 220008121 | 220003252 | 1.9 | 70 | Palliative (P) | null | 2017-11-22 | Carboplatin + Etoposide iv&po | N | Y | 220033863 | CARBOPLATIN + ETOPOSIDE |
| 220008122 | 220003253 | 1.5 | 72.1 | Not known (9) | 2017-05-12 | 2017-05-12 | Carboplatin + Etoposide IV 3 day | 02 | N | 220033868 | CARBOPLATIN + ETOPOSIDE |
| 220008123 | 220003253 | 1.75 | null | Neo-adjuvant (N) | 2014-05-08 | 2014-05-15 | PEMBROLIZUMAB | Y | N | 220033868 | RITUXIMAB |
| 220008124 | 220003253 | 1.6 | 56.4 | Palliative (P) | null | 2014-03-31 | ECX | N | N | 220033868 | ECX |
| 220008125 | 220003253 | null | 95 | Palliative (P) | 2016-01-03 | 2016-01-03 | Oxaliplatin + Modified de Gramont | N | N | 220033868 | OXALIPLATIN + MDG |
| 220008126 | 220020459 | 1.61 | 89 | Curative (C) | 2014-05-13 | 2014-05-13 | AML Int Guide ADE 10+3+5 (1) | N | N | 220033873 | ADE |
| 220008127 | 220020459 | 1.54 | null | Palliative (P) | 2017-12-07 | 2017-12-07 | EOX | N | N | 220033873 | EOX |
| 220008128 | 220020459 | 1.7 | null | Palliative (P) | null | 2016-11-07 | Oxaliplatin + Modified de Gramont | null | null | 220033873 | OXALIPLATIN + MDG |
| 220008129 | 220022024 | 1.6 | 78.6 | Palliative (P) | 2013-12-14 | 2013-12-26 | Carboplatin + Etoposide iv&po | 2 | Y | 220033878 | CARBOPLATIN + ETOPOSIDE |
| 220008130 | 220003254 | 1.6 | 69 | Palliative (P) | 2017-12-06 | 2017-12-06 | GEMCITABINE | N | N | 220033879 | GEMCITABINE |
| 220008131 | 220003254 | 0 | 78.1 | Curative (C) | 2017-08-01 | 2017-08-15 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220033879 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220008132 | 220003254 | 1.71 | 73 | Adjuvant (A) | 2016-04-22 | 2016-06-24 | Cisplatin 100 + RT(H&N) 1 day | 02 | Y | 220033879 | CISPLATIN + RT |
| 220008133 | 220003254 | 1.54 | 77.8 | Palliative (P) | 2015-02-13 | 2015-03-07 | EOX | 02 | N | 220033879 | EOX |
| 220008134 | 220020460 | 1.62 | 53.2 | Palliative (P) | null | 2016-09-04 | EOX | N | N | 220033890 | EOX |
| 220008135 | 220003255 | 1.81 | 80.9 | Disease modification (D) | 2012-10-15 | 2013-02-24 | Cytarabine High Dose | N | N | 220033893 | CYTARABINE HIGH DOSE |
| 220008136 | 220003256 | 1.84 | null | null | 2015-12-20 | 2016-02-24 | Rituximab | 2 | N | 220033896 | RAVVA TRIAL |
| 220008137 | 220003257 | null | 13.4 | Palliative (P) | 2015-03-10 | 2015-03-26 | EOX | N | N | 220033898 | EOX |
| 220008138 | 220011800 | 1.6 | 80.4 | Palliative (P) | 2017-12-04 | 2017-12-04 | Carboplatin + Etoposide IV 3 day | 02 | N | 220033903 | CARBOPLATIN + ETOPOSIDE |
| 220008139 | 220003258 | 1.64 | 77.8 | Palliative (P) | 2015-10-06 | 2015-10-23 | EOX | N | N | 220033904 | EOX |
| 220008140 | 220003259 | null | null | Curative (C) | 2014-11-15 | 2014-11-15 | AML Int Guide ADE 10+3+5 (1) | N | null | 220033910 | ADE |
| 220008141 | 220011801 | 1.78 | 97.4 | Curative (C) | 2013-06-10 | 2013-07-19 | ADE | N | N | 220033911 | ADE |
| 220008142 | 220011801 | 1.56 | 12.5 | Palliative (P) | 2015-08-07 | 2015-08-14 | ECX | N | N | 220033911 | ECX |
| 220008143 | 220011801 | 1.7 | 56 | Curative (C) | 2014-03-14 | 2014-03-14 | ADE 10+3+5 | 01 | N | 220033911 | ADE |
| 220008144 | 220003260 | 1.65 | 92 | Disease modification (D) | null | 2015-12-30 | PEMBROLIZUMAB | N | N | 220033923 | PEMBROLIZUMAB |
| 220008145 | 220003260 | 0 | 84 | Curative (C) | 2015-10-15 | 2015-10-16 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220033923 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220008149 | 220003262 | 1.63 | null | Palliative (P) | 2017-08-22 | 2017-09-05 | EOX | 2 | N | 220033933 | EOX |
| 220008150 | 220003263 | 1.72 | null | Palliative (P) | 2015-02-19 | 2015-02-19 | PEMBROLIZUMAB | 02 | N | 220033934 | RAVVA TRIAL |
| 220008151 | 220003264 | 1.6 | null | Curative (C) | null | 2017-07-29 | Cytarabine High Dose | Y | N | 220033935 | CYTARABINE HIGH DOSE |
| 220008152 | 220011804 | 1.57 | 68 | Neo-adjuvant (N) | 2015-04-08 | 2015-04-08 | RAVVA TRIAL | 02 | N | 220033937 | GEMCITABINE |
| 220008153 | 220011804 | 1.8 | 70 | Adjuvant (A) | 2017-03-31 | 2017-05-02 | CISPLATIN + RT | N | N | 220033937 | CISPLATIN + RT |
| 220008154 | 220011804 | 1.65 | 8.8 | Curative (C) | null | 2014-09-08 | AML Int Guide ADE 10+3+5 (1) | N | N | 220033937 | ADE |
| 220008155 | 220011804 | 1.5 | 54.5 | Disease modification (D) | 2014-09-01 | 2014-09-02 | Cisplatin + Radiotherapy | N | N | 220033937 | CISPLATIN + RT |
| 220008156 | 220003265 | 1.71 | 96 | Not known (9) | 2015-02-26 | 2015-02-26 | RAVVA TRIAL | N | null | 220033944 | GEMCITABINE |
| 220008157 | 220003266 | 1.7 | 74 | Curative (C) | 2014-11-16 | 2014-11-16 | Cytarabine High Dose | null | null | 220033949 | CYTARABINE HIGH DOSE |
| 220008158 | 220003266 | 1.75 | 78.8 | Curative (C) | 2013-10-28 | 2013-10-30 | FLAG | N | N | 220033949 | FLAG |
| 220008159 | 220003267 | 1.64 | 44.9 | Not known (9) | 2015-07-11 | 2015-07-11 | EOX | N | N | 220033952 | EOX |
| 220008160 | 220003268 | 1.71 | 78.8 | Curative (C) | null | 2015-05-16 | Cisplatin + Radiotherapy + CISPLATIN | N | N | 220033953 | CISPLATIN + RT |
| 220008161 | 220011806 | 1.55 | 53 | Palliative (P) | 2013-06-23 | 2013-06-29 | EOX | N | N | 220033955 | EOX |
| 220008162 | 220011806 | null | 89 | Palliative (P) | 2013-09-04 | 2013-09-15 | Carboplatin + Etoposide iv&po | N | N | 220033955 | CARBOPLATIN + ETOPOSIDE |
| 220008163 | 220011806 | 1.52 | null | Palliative (P) | 2013-06-12 | 2013-06-25 | Oxaliplatin + Modified de Gramont | N | N | 220033955 | OXALIPLATIN + MDG |
| 220008164 | 220011806 | 1.28 | 68.3 | Palliative (P) | 2013-11-28 | 2013-12-11 | Oxaliplatin + Modified de Gramont | N | N | 220033955 | OXALIPLATIN + MDG |
| 220008165 | 220011806 | 1.62 | 50.15 | Palliative (P) | 2016-04-13 | 2016-04-26 | Carboplatin AUC 2 - 5 | N | null | 220033955 | CARBOPLATIN |
| 220008166 | 220011806 | 1.62 | null | Palliative (P) | null | 2016-02-05 | RAVVA TRIAL | 02 | N | 220033955 | PEMBROLIZUMAB |
| 220008167 | 220003269 | 1.65 | 95.8 | Adjuvant (A) | 2017-05-24 | 2017-05-25 | CISPLATIN + RT | N | null | 220033971 | CISPLATIN + RT |
| 220008168 | 220003270 | 1.84 | null | Curative (C) | 2015-11-10 | 2015-11-11 | AML Int Guide HD Cytarabine (3 + 4) | 1 | N | 220033972 | CYTARABINE HIGH DOSE |